Back

Interleukin-1 blockade in patients with ST-segment elevation myocardial infarction with and without history of coronary artery disease

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Chronic coronary syndromes: residual and non-traditional risk Inflammation and Immunity ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Rocio I Lopez

University of Virginia Medical Center, Charlottesville (United States of America)

7 More presentations in this session

Presentation thumbnail
Clinical characteristics and predictors of mortality in patients with refractory angina due to obstructive and non-obstructive chronic coronary syndromes: a contemporary retrospective cohort study.
Doctor K. Cheng (London, GB)
Abstract Slides Video
Presentation thumbnail
Exploring residual cardiovascular risk beyond LDL cholesterol in patients with acute destabilisation of known significant atherosclerosis
Doctor L. Bavuso (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Biological age as a new risk factor for myocardial Infarction?
Miss I. Nemere (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Chest pain and cardiac troponin flat curve: six-month prognosis of a cohort of patients
Doctor P. Awamleh Garcia (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Proteomic characterization of human coronary artery reveals different pathological stages of atherosclerosis
Doctor X. Xu (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic coronary syndromes: residual and non-traditional risk

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Diabetes mellitus and response to IL-1 blockade with Anakinra after ST-elevation myocardial infarction: a pooled analysis of the VCU-ART studies
thumbnail
Congress Presentation
Resolution of systemic inflammation in patients with recently decompensated heart failure with reduced ejection fraction with and without interleukin-1 blockade by anakinra
thumbnail
Congress Presentation
Effect of interleukin 1b inhibition with canakinumab on inflammation and viral persistence in people with human immunodeficiency virus

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources